<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1018">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01702805</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0050</org_study_id>
    <secondary_id>U01HL112776</secondary_id>
    <secondary_id>U01HL112748</secondary_id>
    <nct_id>NCT01702805</nct_id>
  </id_info>
  <brief_title>Transfusion of Prematures Trial</brief_title>
  <acronym>TOP</acronym>
  <official_title>Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the TOP trial is to determine whether higher hemoglobin thresholds for
      transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the
      primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months
      of age, using standardized assessments by Bayley.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term outcomes of extremely low birth weight (ELBW) preterm infants, those weighing less
      than or equal to 1000 g at birth, are poor and pose a major health care burden. Virtually
      all of these infants are transfused, but at inconsistent hemoglobin (Hgb) thresholds.

      The investigators propose in TOP to randomize infants less than or equal to 1000 g BW and &lt;
      29 weeks GA to receive red blood cell (RBC) transfusions according to one of two strategies
      of Hgb thresholds, either a high Hgb (liberal transfusion) or a low Hgb (restrictive
      transfusion) algorithm. It is currently unknown which transfusion strategy is superior. TOP
      is powered to demonstrate which strategy reduces the primary outcome of death or
      neurodisability in survivors at 22-26 months.

      A secondary study entitled &quot;Effect of Blood Transfusion Practices on Cerebral and Somatic
      Oximetry&quot;, also known as the NIRS study, will determine differences in cerebral oxygenation
      and fractional tissue oxygen extraction with NIRS between high and low hemoglobin threshold
      groups during red blood cell transfusions. The investigators also propose to determine
      whether abnormal cerebral NIRS measures are a better predictor of NDI than hemoglobin alone
      and whether abnormal mesenteric NIRS measures are associated with the development of NEC
      within the 48 hours following a transfusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Death or significant neurodevelopmental impairment</measure>
    <time_frame>Birth to 22-26 months corrected gestational age</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of children surviving without significant neurodevelopmental impairment at 22-26 months of corrected age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 IVH, cystic PVL, or ventriculomegaly</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe cerebral palsy</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of necrotizing enterocolitis</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Episodes of NEC Bell stage II or higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to full feeds</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The amount of time it takes for infant to achieve full feeds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of transfusions, numbers of donor exposures by RBC donors or other blood product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at final tracheal extubation</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at final caffeine dose</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Weight, length, and head circumference at 36 weeks postmenstrual age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to discharge without severe morbidity</measure>
    <time_frame>Birth to 36 weeks PMA</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival to discharge without severe morbidity, defined as any of the following: bronchopulmonary dysplasia, retinopathy of prematurity (stage &gt;3 or requiring treatment), or serious brain abnormality (grade 3 or 4 intraventricular hemorrhage, periventricular leukomalacia, or ventriculomegaly).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory disease</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The presence of respiratory disease necessitating readmission before 22-26 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hydrocephalus shunt, microcephaly, or seizure disorder</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic cost-benefit analysis</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1824</enrollment>
  <condition>Infant, Newborn, Diseases</condition>
  <condition>Infant, Extremely Low Birth Weight</condition>
  <condition>Infant, Small for Gestational Age</condition>
  <condition>Bronchopulmonary Dysplasia (BPD)</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Low Threshold Transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Threshold Transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusions will be administered using a higher threshold hemoglobin value.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liberal Cell Transfusion</intervention_name>
    <arm_group_label>High Threshold Transfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Restricted red cell transfusion</intervention_name>
    <arm_group_label>Low Threshold Transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight less than 1000 grams.

          -  Gestational age at least 22 weeks but less than 29 completed weeks

          -  Admitted to the NICU within 48 hours of life

        Exclusion Criteria:

          -  Considered nonviable by the attending neonatologist

          -  Cyanotic congenital heart disease

          -  Parents opposed to the transfusion of blood

          -  Parents with hemoglobinopathy or congenital anemia

          -  In-utero fetal transfusion

          -  Twin-to-twin transfusion syndrome

          -  Isoimmune hemolytic disease

          -  Lack of parental consent

          -  Severe acute hemorrhage, acute shock, sepsis with coagulopathy, or need for
             perioperative transfusion.

          -  Prior blood transfusion on clinical grounds beyond the first 6 hours of life

          -  High probability that the family is socially disorganized to the point of being
             unable to attend follow-up at 22-26 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele C Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beena Sood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbot R Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Cotten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ravi Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Sokol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myra Wyckoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A Kennedy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl T D'Angio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Truog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haresh M Kirpalani, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haresh M Kirpalani, MD</last_name>
    <phone>215-590-1653</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosemary Higgins, MD</last_name>
    <phone>(301) 435-5575</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar A. Carlo, MD</last_name>
      <phone>205-934-4680</phone>
    </contact>
    <investigator>
      <last_name>Waldemar A. Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uday Devaskar, MD</last_name>
      <phone>310-825-9314</phone>
    </contact>
    <investigator>
      <last_name>Uday Devaskar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisa P. Van Meurs, MD</last_name>
      <phone>650-723-5711</phone>
    </contact>
    <investigator>
      <last_name>Krisa P. Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Patel, MD</last_name>
      <phone>404-727-5905</phone>
    </contact>
    <investigator>
      <last_name>Barbara J. Stoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Sokol, MD</last_name>
      <phone>317-274-4715</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F. Bell, MD</last_name>
      <phone>319-356-4006</phone>
    </contact>
    <investigator>
      <last_name>Edward F. Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seetha Shankaran, MD</last_name>
      <phone>313-745-1436</phone>
    </contact>
    <investigator>
      <last_name>Seetha Shankaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Truog, MD</last_name>
      <phone>816-234-3592</phone>
    </contact>
    <investigator>
      <last_name>William Truog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Ohls, MD</last_name>
      <phone>505-272-0180</phone>
    </contact>
    <investigator>
      <last_name>Kristi L. Watterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronnie Guillet, MD</last_name>
      <phone>585-275-6209</phone>
    </contact>
    <investigator>
      <last_name>Carl T D'Angio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald N. Goldberg, MD</last_name>
      <phone>919-681-6024</phone>
    </contact>
    <investigator>
      <last_name>Ronald N. Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Michael Cotten, MD MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Schibler, MD</last_name>
      <phone>513-636-3972</phone>
    </contact>
    <investigator>
      <last_name>Kurt Schibler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele C. Walsh, MD MS</last_name>
      <phone>216-844-3387</phone>
    </contact>
    <investigator>
      <last_name>Michele C. Walsh, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leif Nelin, MD</last_name>
      <phone>614-355-6724</phone>
    </contact>
    <investigator>
      <last_name>Leif Nelin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haresh Kirpalani, MD</last_name>
      <phone>215-590-1653</phone>
    </contact>
    <investigator>
      <last_name>Barbara Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abbot R. Laptook, MD</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>43200</phone_ext>
    </contact>
    <investigator>
      <last_name>Abbot R. Laptook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myra Wyckoff, MD</last_name>
      <phone>214-648-3923</phone>
    </contact>
    <investigator>
      <last_name>Myra Wyckoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen A. Kennedy, MD MPH</last_name>
      <phone>713-500-6708</phone>
    </contact>
    <investigator>
      <last_name>Kathleen A. Kennedy, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon E. Tyson, MD MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org/</url>
    <description>NICHD NRN Website</description>
  </link>
  <link>
    <url>http://www.nichd.nih.gov/about/org/cdbpm/pp/index.cfm</url>
    <description>NICHD Pregnancy &amp; Perinatology Branch</description>
  </link>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 21, 2015</lastchanged_date>
  <firstreceived_date>August 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NICHD Neonatal Research Network</keyword>
  <keyword>Very Low Birth Weight (VLBW)</keyword>
  <keyword>Extremely Low Birth Weight (ELBW)</keyword>
  <keyword>Transfusions</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
